Tal Kan

Dr. Tal Kan

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YBYiftah Barsheshet
Yiftah Barsheshet
TVTali Voloshin
Tali Voloshin
BBBoris Brant
Boris Brant
GCGadi Cohen
Gadi Cohen
LKLilach Koren
Lilach Koren
YPYoram Palti
Yoram Palti
Tumor Treating Fields (TTFields) are electric fields that exert physical forces to disrupt cellular processes critical for cancer cell viability and tumor progression. TTFields induce anti-mitotic effects through the disruption of the mitotic spindle and abnormal chromosome segregation, which trigger several forms of cell death, including immunogenic cell death (ICD). The efficacy of TTFields concomitant with anti-programmed death-1 (anti-PD-1) treatment was previously shown in vivo and is currently under clinical investigation. Here, the potential of TTFields concomitant with anti- PD-1/anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) or anti-programmed death-ligand 1 (anti-PD-L1) immune checkpoint inhibitors (ICI) to improve therapeutic efficacy was examined in lung tumor-bearing mice. Increased circulating levels of high mobility group box 1 protein (HMGB1) and elevated intratumoral levels of phosphorylated eukaryotic translation initiation factor 2α (p-eIF2α) were found in the TTFields-treated mice, indicative of ICD induction. The concomitant application of TTFields and ICI led to a significant decrease in tumor volume as compared to all other groups. In addition, significant increases in the number of tumor-infiltrating immune cells, specifically cytotoxic T-cells, were observed in the TTFields plus anti-PD-1/anti-CTLA-4 or anti-PD-L1 groups. Correspondingly, cytotoxic T-cells isolated from these tumors showed higher levels of IFN-γ production. Collectively, these results suggest that TTFields have an immunoactivating role that may be leveraged for concomitant treatment with ICI to achieve better tumor control by enhancing antitumor immunity.

27 January 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
SDShiri Davidi
Shiri Davidi
EFElla Fremder
Ella Fremder
TKTal Kan
Tal Kan
ZRZiv Raviv
Ziv Raviv
MTMichael Timaner
Michael Timaner
YSYuval Shaked
Yuval Shaked
The antiangiogenic role of the pro-inflammatory cytokine interleukin-31

30 June 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
BKBella Koltun
Bella Koltun
TVTali Voloshin
Tali Voloshin
CDCfir David
Cfir David
TKTal Kan
Tal Kan
YBYiftah Barsheshet
Yiftah Barsheshet
YPYoram Palti
Yoram Palti
Multidrug resistance (MDR) is a major challenge in cancer treatment. One predominant MDR mechanism involves the overexpression of ATP-binding cassette transporter proteins on the cell membrane, leading to increased chemotherapy efflux. Strategies to resolve MDR have not yet yielded substantial survival benefits. Tumor Treating Fields (TTField) represent an innovative therapeutic modality for cancer treatment and have been shown to enhance membrane permeability in glioblastoma cells. The current study aimed to characterize this phenomenon and evaluate its potential to increase chemotherapy accumulation, thus overcoming MDR. In vitro analyses using the exclusion dye 7-aminoactinomycin D demonstrated that TTFields-induced enhancement of membrane permeability is pan-cancer while specific to cancer cells, reversible, and requires cell-cycle progression through the G2–M phase. Furthermore, TTFields significantly increased intracellular accumulation of doxorubicin (DOX), mitoxantrone, and cisplatin in resistant cells, restoring uptake to levels observed in sensitive cells, without altering MDR transporter expression. Increased chemotherapy accumulation was confirmed in vivo as demonstrated by elevated DOX accumulation in breast tumors and increased paclitaxel accumulation in lung tumors. Importantly, TTFields sensitized both DOX-sensitive and DOX-resistant cells to DOX-induced cytotoxicity in vitro. In mouse models bearing breast tumors, co-administration of therapeutic or sub-therapeutic DOX doses together with TTFields significantly reduced tumor growth compared with either treatment alone. In conclusion, the findings suggest that adding TTFields to chemotherapy regimens may enhance drug delivery and efficacy in tumors exhibiting MDR. Further clinical studies evaluating TTFields concomitant with chemotherapy in patients with MDR cancer are warranted.

Verified
Journal Article
Open access
PDF file
TKTal Kan
Tal Kan
YBYiftah Barsheshet
Yiftah Barsheshet
TKTharwat Haj Khalil
Tharwat Haj Khalil
BBBoris Brant
Boris Brant
TVTali Voloshin
Tali Voloshin
YPYoram Palti
Yoram Palti
Tumor-associated macrophages (TAMs) are abundant in the tumor microenvironment (TME) and often adopt an M2-like immunosuppressive phenotype that promotes tumor growth. Reprogramming TAMs toward an M1-like pro-inflammatory state is an attractive therapeutic strategy. Tumor Treating Fields (TTFields), an FDA-approved, electric-field–based therapy, has recently been suggested to modulate immune responses in addition to its established anti-mitotic activity. Here, we investigated the direct effects of TTFields on macrophage activation and function. Murine bone marrow–derived macrophages (BMDMs) were polarized toward a pro-inflammatory M1-like phenotype or an anti-inflammatory M2-like phenotype and exposed to TTFields. TTFields rapidly activated guanine nucleotide exchange factor-H1 (GEF-H1), and downstream nuclear factor kappa B (NF-κB) and activator protein-1 (AP-1, via c-Jun N-terminal kinase [JNK]) signaling. Functionally, TTFields reprogrammed M2-like macrophages by increasing major histocompatibility complex class II (MHC-II) and cluster of differentiation 80 (CD80); reducing arginase-1 (Arg1); and elevating secretion of chemokine (C-X-C motif) ligand 1 (CXCL1), interleukin-6 (IL-6), IL-1β, and IL-12 subunit p70 (IL-12p70). In interferon gamma (IFN-γ)-primed macrophages, TTFields provided a secondary signal, driving myeloid differentiation primary response 88 (MyD88)-dependent expression of inducible nitric oxide synthase (iNOS). In vivo, TTFields reduced tumor burden in an orthotopic murine lung cancer model and increased iNOS expression in both M1-like and a subset of M2-like TAMs. These findings demonstrate that TTFields directly reprogram macrophages toward a pro-inflammatory phenotype, suggesting a novel immunomodulatory mechanism that may enhance anti-tumor immunity in the TME.

3 November 2025
Verified
Other
Open access
BKBella Koltun
Bella Koltun
TVTali Voloshin
Tali Voloshin
CDCfir David
Cfir David
TKTal Kan
Tal Kan
YBYiftah Barsheshet
Yiftah Barsheshet
YPYoram Palti
Yoram Palti
DOX dose-response curves and TTFields sensitization to DOX cytotoxic effects.

3 November 2025
Verified
Other
Open access
BKBella Koltun
Bella Koltun
TVTali Voloshin
Tali Voloshin
CDCfir David
Cfir David
TKTal Kan
Tal Kan
YBYiftah Barsheshet
Yiftah Barsheshet
YPYoram Palti
Yoram Palti
Characterization of MDR transporter expression in parental and resistant cell lines.